⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720974 | 0.81 | TSHR (0.33) | — | |
| SCHEMBL2468579 | 0.78 | LMNA (0.32) | — | |
| SCHEMBL20018290 | 0.76 | CA14 (0.36) | — | |
| SCHEMBL871607 | 0.75 | — | — | |
| SCHEMBL376713 | 0.74 | — | — | |
| SCHEMBL1132975 | 0.71 | CA12 (0.31) | — | |
| SCHEMBL2086403 | 0.71 | CA12 (0.43) | — | |
| SCHEMBL15017086 | 0.71 | ALOX5 (0.41) | — | |
| SCHEMBL657409 | 0.70 | KDM4E (0.31) | — | |
| SCHEMBL21682376 | 0.70 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| EP-3388427-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20210107868-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2021-04-15 | — | — | US | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| WO-2020166680-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 大鵬薬品工業株式会社 | 2020-08-20 | — | — | WO | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| US-20130116283-A1 | Substituted indole derivatives | Grünenthal GmbH (DE) | 2013-05-09 | — | — | US | disclosed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2356101-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2254883-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009103552-A1 | SUBSTITUTED INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20090215828-A1 | Substituted indole derivatives | GRUNENTHAL GMBH (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090105212-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1939201-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |